Business
Collegium Announces Eight Poster Presentations at PAINWeek Conference 2024
STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company
About this update from Collegium Pharmaceutical, Inc.
[{"type":"text","content":"STOUGHTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that eight poster presentations highlighting data regarding its diversified pain portfolio will be presented at PAINWeek Conference 2024, being held in Las Vegas, NV, from September 3–6, 2024. “Collegium is proud to present new real-world data at PAINWeek 2024 as part of our commitment to leading with science and responsible pain management,” said Thomas Smith, M.D., Chief Medical Officer of Collegium. “The eight posters demonstrate the clinical and population health impact of our meaningfully differentiated pain portfolio and provide important insights for healthcare decision makers who treat people with pain. We welcome opportunities to share clinical and real-world data with the medical community as we advance our mission to improve the lives of people living with serious medical conditions.” The following posters will be available and on display to attendees in the Exhibit Hall from 10:30 a.m. PT on Wednesday, September 4, 2024, to 2:45 p.m. PT on Friday, September 6, 2024. Poster Presentations: Poster Title:Healthcare Costs and Resource Use among Chronic Low Back Pain Patients Treated with Belbuca® or Buprenorphine Transdermal Patches: A Retrospective US Medicare Claims AnalysisAuthors:Vladimir Zah, D.Phil.; Filip Stanicic, M.Pharm, MSC; Dimitrije Grbic, M.Pharm., Ph.D. Poster Title:Treatment Characteristics and Dosing Patterns in Chronic Low Back Pain Patients Treated with Belbuca® and Buprenorphine Transdermal Patches: A Retrospective US Medicare Claims AnalysisAuthors:Filip Stanicic, M.Pharm., MSC; Vladimir Zah, D.Phil,; Dimitrije Grbic, M.Pharm., Ph.D. Poster Title:Safety and Tolerability of Schedule III Buprenorphine and Oral Schedule II Opioid Treatment in Chronic Low Back Pain Patients: A Retrospective US Medicare Claims AnalysisAuthors:Dimitrije Grbic, M.Pharm., Ph.D.; Filip Stanicic, M.Pharm., MSC; Vladimir Zah, D.Phil, Poster Title:Comparison of Nonmedical Use of Buprenorphine Products for Analgesia Compared to Other Opioid Medications in Adults Evaluated for Substance Use with the Addiction Severity Index-Multimedia Version (ASI-MV®)Authors:Jody Green, Ph.D.; Kait...